Novo Holdings and experienced venture capitalists on both sides of the Atlantic have come together to create a new fund focused on rare diseases. Led by VCs who spent years at Lundbeckfonden Ventures and NEA, Sound Bioventures will use its initial 110 million euros ($124 million) to back biotechs that are either in or on the cusp of the clinic.
Image: Novo Holdings framed its interest in Sound Bioventures as about more than just generating a return on investment. ((Pixabay))